化疗后PET/CT在弥漫大B细胞淋巴瘤疗效评价中的价值

Value of PET/CT after Chemotherapy for Evaluating Therapentic Efficacy of Patients with Diffuse Large B-cell Lymphoma

目的:探讨化疗后PET/CT显像在弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)疗效评价中的价值。方法:收集2005年9月至2012年1月73例DLBCL患者化疗前和化疗6-8周期后行18F-FDG PET/CT的显像检查资料并比较这些患者化疗前后2次PET/CT检查的结果,将患者分为完全缓解组、部分缓解组及未缓解组。应用无进展生存(progression-free survival,PFS)率及总体生存(overall survival,OS)率作为指标,评价化疗后PET/CT对疗效评价能力。结果:化疗后PET/CT结果显示,完全缓解组、部分缓解组及未缓解组患者的2年PFS率及3年OS率分别为82%(41/50)和88%(44/50)、45.5%(5/11)和54.5%(6/11)、8.3%(1/12)和8.3%(1/12),3组间差异均非常显著(均P<0.01)。完全缓解组、部分缓解组的2年PFS率及3年OS率均显著高于未缓解组(均P<0.05);完全缓解组与部分缓解组的2年PFS率及3年OS率比较,差异显著,也具有统计学意义(均P<0.05)。结论:化疗后应用PET/CT显像技术能够准确的评价DLBCL患者的化疗疗效及预后。

Objective:To investigate the value of PET/CT after chemotherapy for evaluating therapeutic efficacy of patients with diffuse large B-cell lymphoma（DLBCL）.Methods:18F-FDG PET/CT was performed before and after 6-8 cycles of chemotherapy in 73 newly diagnosed patients with DLBCL from September 2005 to January 2012.The results of pre-treatment PET/CT was compared with results of post-treatment PET/CT.These patients were divided into3 groups:complete response group,partial response group and no response group.The post-treatment PET/CT results was used to assess its ability to predict progression-free survival（PFS） and overall survival（OS）.Results:The comparison of PET/CT results before and after chemotherapy showed that 2-year PFS rates of complete response group,partial response group and no response group were 82%（41/50）,45.5%（5/11） and 8.3%（1/12）,respectively;and the 3-year OS rates of 3 groups were 88%（44/50）,54.5%（6/11） and 8.3%（1/12） respectively（both P < 0.01）.The 2-year PFS rate and the 3-year OS rate of the complete response group and partial response group were significantly higher than those of no response group（both P < 0.05）,and there was also significant statistical difference between partial response group and complete response group in 2-year PFS rate and 3-year OS rate（both P < 0.05）.Conclusion:The post-treatment PET/CT can be accurately used to evaluate the curative efficacy of chemotherapy and prognosis of patients with DLBCL.